MiRXES, a biotechnology company from Singapore, is introducing its developed non-invasive gastric cancer test technology to the Japanese market through a partnership.

Principle and Advantages of the New Technology: Jerry's GASTROClear detector evaluates the risk of gastric cancer by analyzing small molecule ribonucleic acids (microRNAs) in the blood. Compared to traditional endoscopy, this method enables non-invasive screening with just a blood test and is expected to increase the public's willingness to undergo screening.

Expansion into the Japanese market: In July 2025, Mirai signed a memorandum of cooperation with Japan's Chowa Pharmaceutical Company, under which Chowa Pharmaceutical will manufacture this measuring device locally and establish a distribution network. Both parties also plan to offer early gastric cancer screenings free of charge to 10,000 people in Japan. Former Prime Minister Yukio Hatoyama supported this screening initiative, stating that it could reduce the nation's healthcare costs.